ESMO 2017 MTI- Disease management and comprehensive genomic profiling in cancer of unknown primary

Nov 01, 2017

This seminar describes the current standard of care, molecular testing, a discussion of clinical cases and genomic profiling for patients with cancers of unknown primary site. ▼alectinib, ▼pertuzumab, ▼cobimetinib, ▼olaparib, ▼vismodegib, ▼pembrolizumab, ▼crizotinib: ▼These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please see safety reporting on the contact us page via the site menu.

Current View